Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography

The use of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) for response assessment in lymphoma is now widespread. Prognostic information obtained from PET performed after two to three cycles of chemotherapy may guide more individualized, risk-adapted therapeutic strategies. Progress...

Descripción completa

Detalles Bibliográficos
Autor principal: Kasamon, Yvette L.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021845/
https://www.ncbi.nlm.nih.gov/pubmed/21253532
http://dx.doi.org/10.1155/2011/271595
_version_ 1782196428102172672
author Kasamon, Yvette L.
author_facet Kasamon, Yvette L.
author_sort Kasamon, Yvette L.
collection PubMed
description The use of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) for response assessment in lymphoma is now widespread. Prognostic information obtained from PET performed after two to three cycles of chemotherapy may guide more individualized, risk-adapted therapeutic strategies. Progress in the risk stratification of Hodgkin's lymphoma through midtreatment PET is reviewed, with a focus on management implications in newly diagnosed and relapsed disease. How to tailor treatment on the basis of the interim PET result is not yet defined but is the subject of ongoing trials.
format Text
id pubmed-3021845
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30218452011-01-20 Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography Kasamon, Yvette L. Adv Hematol Review Article The use of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) for response assessment in lymphoma is now widespread. Prognostic information obtained from PET performed after two to three cycles of chemotherapy may guide more individualized, risk-adapted therapeutic strategies. Progress in the risk stratification of Hodgkin's lymphoma through midtreatment PET is reviewed, with a focus on management implications in newly diagnosed and relapsed disease. How to tailor treatment on the basis of the interim PET result is not yet defined but is the subject of ongoing trials. Hindawi Publishing Corporation 2011 2010-12-22 /pmc/articles/PMC3021845/ /pubmed/21253532 http://dx.doi.org/10.1155/2011/271595 Text en Copyright © 2011 Yvette L. Kasamon. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kasamon, Yvette L.
Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
title Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
title_full Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
title_fullStr Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
title_full_unstemmed Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
title_short Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
title_sort prognostication and risk-adapted therapy of hodgkin's lymphoma using positron emission tomography
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021845/
https://www.ncbi.nlm.nih.gov/pubmed/21253532
http://dx.doi.org/10.1155/2011/271595
work_keys_str_mv AT kasamonyvettel prognosticationandriskadaptedtherapyofhodgkinslymphomausingpositronemissiontomography

Ejemplares similares